Discovery and Preclinical Profiling of 3‑[4-(Morpholin-4-yl)‑7H‑pyrrolo[2,3‑d]pyrimidin-5-yl]benzonitrile (PF-06447475), a Highly Potent, Selective, Brain Penetrant, and in Vivo Active LRRK2 Kinase Inhibitor
journal contributionposted on 08.01.2015 by Jaclyn L. Henderson, Bethany L. Kormos, Matthew M. Hayward, Karen J. Coffman, Jayasankar Jasti, Ravi G. Kurumbail, Travis T. Wager, Patrick R. Verhoest, G. Stephen Noell, Yi Chen, Elie Needle, Zdenek Berger, Stefanus J. Steyn, Christopher Houle, Warren D. Hirst, Paul Galatsis
Any type of content formally published in an academic journal, usually following a peer-review process.
Leucine rich repeat kinase 2 (LRRK2) has been genetically linked to Parkinson’s disease (PD) by genome-wide association studies (GWAS). The most common LRRK2 mutation, G2019S, which is relatively rare in the total population, gives rise to increased kinase activity. As such, LRRK2 kinase inhibitors are potentially useful in the treatment of PD. We herein disclose the discovery and optimization of a novel series of potent LRRK2 inhibitors, focusing on improving kinome selectivity using a surrogate crystallography approach. This resulted in the identification of 14 (PF-06447475), a highly potent, brain penetrant and selective LRRK2 inhibitor which has been further profiled in in vivo safety and pharmacodynamic studies.